Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
← catalyst calendarNCT06829823 · readout ≤ 103 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
20estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Nov 2025 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
- Drug: N-803 and BCG — also filed as BCG, N-803, Bacillus Calmette-Guérin
- Drug: N-803 and Gemcitabine — also filed as N-803, Gemcitabine, Gemzar
Primary outcome
what the primary-completion date above is the date OFEfficacy of Arms A and B at Month 3 and Month 6
measured At Month 3 and Month 6
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed